Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction

OBJECTIVE To evaluate the role of plasma neurohormones in the diagnosis of asymptomatic or minimally symptomatic right ventricular dysfunction. SETTING Tertiary cardiovascular referral centre. METHODS Plasma brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) concentrations were measured in 21 asymptomatic or minimally symptomatic patients with chronic right ventricular pressure overload caused by congenital heart disease, and in seven healthy volunteers. Right ventricular ejection fraction was determined using magnetic resonance imaging. RESULTS Right ventricular ejection fraction in the volunteers was higher than in the patients (69.0 (8.2)% v 58.0(12.0)%, respectively; p < 0.006). Left ventricular ejection fraction was 72.3(7.8)% in volunteers and 68.1(11.0)% in patients (NS). There was a significant difference between patients and volunteers in the plasma concentrations of BNP (5.3 (3.5) v 2.3 (1.7) pmol/l, respectively; p < 0.009) and ANP (7.3 (4.5)v 3.6 (1.4) pmol/l; p < 0.05). In both patients and volunteers, mean plasma ANP was higher than mean plasma BNP. Right ventricular ejection fraction was inversely correlated with BNP and ANP (respectively, r = 0.65; p < 0.0002 and r = 0.61; p < 0.002). There was no correlation between left ventricular ejection fraction and BNP (r = 0.2; NS) or ANP (r = 0.52; NS). Similarly, no correlation was shown between the level of right ventricular systolic pressure and either plasma BNP (r = 0.20) or plasma ANP (r = 0.07). CONCLUSIONS There was a significant inverse correlation between right ventricular ejection fraction and the plasma neurohormones BNP and ANP in asymptomatic or minimally symptomatic patients with right ventricular pressure overload and congenital heart disease. Monitoring changes in BNP and ANP may provide quantitative follow up of right ventricular dysfunction in these patients.

[1]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[2]  D. Barnett,et al.  Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. , 1999, European heart journal.

[3]  Y. Pinto,et al.  High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. , 1998, Journal of the American College of Cardiology.

[4]  W. Shimizu,et al.  Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. , 1998, Circulation.

[5]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[6]  H. Crijns,et al.  Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure. , 1998, European heart journal.

[7]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[8]  D. Fassbender,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: identification of the target vessel by myocardial contrast echocardiography , 1998 .

[9]  W P Santamore,et al.  Can indices of left ventricular function be applied to the right ventricle? , 1998, Progress in cardiovascular diseases.

[10]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.

[11]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[12]  P. Oldershaw,et al.  The difficulties of assessing right ventricular function. , 1995, British heart journal.

[13]  A. Roos,et al.  Evaluation of cardiac function with magnetic resonance imaging. , 1994, American heart journal.

[14]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[15]  A. Roos,et al.  Magnetic resonance measurement of velocity and flow: technique, validation, and cardiovascular applications. , 1993, American heart journal.

[16]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[17]  C. Lang,et al.  Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. , 1992, Clinical science.

[18]  T. Graham,et al.  Ventricular performance in congenital heart disease. , 1991, Circulation.

[19]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[20]  E. Theodorsson,et al.  Raised plasma concentrations of atrial natriuretic peptide are independent of left atrial dimensions in patients with chronic atrial fibrillation. , 1990, British heart journal.